RESUMO
Sprague Dawley rats were subjected to acute myocardial infarction (AMI) by permanent ligation of the left anterior descending coronary artery. At the time of AMI, a subcutaneous mini-osmotic pump was implanted and animals were randomized into three groups, according to the intravenous therapy received during the first 72 h: placebo-treated (saline), serelaxin10-treated (SRLX10 = 10 µg/kg/day), or serelaxin30-treated (SRLX30 = 30 µg/kg/day). Treatment with SRLX30 reduced the expression of inflammatory cytokines and chemokines, as well as the infiltration of macrophages, and increased the expression of pro-angiogenic markers and vessel density in the infarcted myocardium after 7 days. SRLX30 did not reduce early myocardial fibrosis but reduced myocardial levels of sST2 and galectin-3. No significant effects were observed with SRLX10 treatment. A significant correlation was observed between plasma levels of serelaxin and effect measures. The results suggest serelaxin has a protective effect in early processes of cardiac remodeling after AMI.
Assuntos
Indutores da Angiogênese/administração & dosagem , Proteínas Angiogênicas/metabolismo , Anti-Inflamatórios/administração & dosagem , Mediadores da Inflamação/metabolismo , Infarto do Miocárdio/tratamento farmacológico , Neovascularização Fisiológica/efeitos dos fármacos , Relaxina/administração & dosagem , Animais , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Fibrose , Galectina 3/metabolismo , Infusões Intravenosas , Masculino , Infarto do Miocárdio/metabolismo , Infarto do Miocárdio/fisiopatologia , Miocárdio/metabolismo , Miocárdio/patologia , Ratos Sprague-Dawley , Receptores de Interleucina-1/metabolismo , Proteínas Recombinantes/administração & dosagem , Transdução de Sinais/efeitos dos fármacos , Fatores de Tempo , Remodelação Ventricular/efeitos dos fármacosRESUMO
No disponible
